CSIMarket Company Name, Ticker, Suppliers, else..
 
Replimune Group Inc   (NASDAQ: REPL)
 
Price: $13.3800 $0.46 3.560%
Day's High: $13.645000457763672 Week Perf: -9.41 %
Day's Low: $ 12.79 30 Day Perf: -11.92 %
Volume (M): 1,083,288 52 Wk High: $ 16.33
Volume (M$): $ 0 52 Wk Avg: $8.33
Open: $12.97 52 Wk Low: $1.50



 Market Capitalization (Millions $) 1,296
 Shares Outstanding (Millions) 97
 Employees 465
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -297
 Cash Flow (TTM) (Millions $) 26
 Capital Exp. (TTM) (Millions $) 4

Business Description


Replimune Group Inc is a biotechnology company that specializes in the development of oncolytic immunotherapies to treat various forms of cancer. They have developed a platform called Immulytic that combines multiple engineering strategies to enhance the selective replication of viruses within tumors, ultimately leading to the destruction of cancer cells. The company aims to provide better treatment options for patients by harnessing the power of the immune system to fight cancer. Replimune Group Inc is based in Woburn, Massachusetts and was founded in 2015.


   Company Address: 500 Unicorn Park Drive Woburn 1801 MA
   Company Phone Number: 222-9600   Stock Exchange / Ticker: NASDAQ REPL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -13.21%    
EXEL   -4.59%    
GILD   -3.88%    
IOVA        5.52% 
MRNA        0.52% 
NVAX   -7.19%    
• View Complete Report
   



Clinical Study

Promising Advancements in Oncolytic Immunotherapy Replimunes Breakthroughs in Melanoma and Hepatocellular Carcinoma ...

Published Mon, Oct 20 2025 7:31 AM UTC

In a significant stride towards revolutionizing treatment options for melanoma and hepatocellular carcinoma (HCC), Replimune Group, Inc. (NASDAQ: REPL), a pioneering clinical-stage biotechnology firm dedicated to novel oncolytic immunotherapies, has showcased robust data from its innovative therapies at prominent oncology conferences in recent months. During the European Soc...
Announcement

Replimune Group Inc. Shareholders Join Class Action Amidst Financial Setbacks - The Gross Law Firm Calls for Affect...

Published Fri, Sep 19 2025 1:20 AM UTC

NEW YORK, Sept. 18, 2025 The Gross Law Firm has officially reached out to shareholders of Replimune Group, Inc. (NASDAQ: REPL), encouraging those who experienced financial losses to join a class action lawsuit. This legal movement arises in light of the company’s recent undesirable performance in the financial markets, raising serious concerns about corporate governance...
Shares

Replimune Fortifies Workforce Amidst Economic Shifts: Strategic Equity Awards Propel Biotech Innovation,

Published Fri, May 9 2025 8:01 PM UTC

In a significant move aligned with its strategic objectives, Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology firm at the forefront of developing cutting-edge oncolytic immunotherapies, recently announced the granting of inducement equity awards under the Nasdaq Listing Rule 5635(c)(4). This announcement, made on May 9, 2025, highlights the company s comm...
Stock Market Announcement

Navigating Revenue Challenges: Replimune Groups Inducement Equity Awards as a Cornerstone for Workforce Resilience,

Published Fri, Apr 11 2025 8:01 PM UTC

Replimune Group s Strategic Inducement Awards: A Move Towards Workforce Stability Amidst Revenue ChallengesOn April 11, 2025, Replimune Group, Inc. (NASDAQ: REPL), a biotech frontrunner specializing in innovative oncolytic immunotherapies, announced a significant step in employee retention and motivation through the grant of inducement equity awards to newly hired non-execut...
Announcement

Replimune Group, Inc. Announces Inducement Grants for Non-Executive Employees Amidst Diminished Revenue

Published Sat, Jan 11 2025 11:22 AM UTC

Replimune Group, Inc. Inducement Grants Overview Replimune Group, Inc. (NASDAQ: REPL), a biotechnology firm engaged in the development of innovative oncolytic immunotherapies, recently issued a press release regarding the grant of inducement equity awards to newly hired non-executive employees. This announcement, made on January 10, 2025, aligns with the Nasdaq Listing Rule ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 12.27
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.57
Working Capital Ratio 4.7
Leverage Ratio (MRQ) 1.43
Total Debt to Equity 0.8
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.18 $
Revenues (TTM) -
Cash Flow (TTM) 0.26 $
Cash 2.02 $
Book Value 1.09 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -638,738
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.